News

Results demonstrate that XL647 is generally well tolerated and shows evidence of antitumor activity. A maximum tolerated dose has also been established. “The number of patients with prolonged

The phase IIb trial will evaluate the efficacy and safety of once daily, oral dosing of IPL512,602 against placebo. Enrolled in the study are those patients with moderate

By using gene therapy to modify signaling pathways in the brain, researchers found that they could significantly reduce the development of epileptic seizures in rats. “This provides a

Taro said that its meloxicam tablets product is bioequivalent to Boehringer Ingelheim’s Mobic tablets. According to industry sources, branded and generic meloxicam tablet products had US sales of

Graceway Pharmaceuticals will buy 3M’s pharmaceutical operations in the US, Canada and Latin America for $875 million and Swedish-based Meda AB will acquire the company’s European drugs business

In recent published research, the combination of a Vascular Disrupting Agent (VDA) with an antiangiogenic agent was described as offering a powerful and highly targeted regimen for suppressing

Historically, monoclonal antibodies have been ineffective in melanoma. However, scientists at the Albert Einstein College of Medicine believe they have developed a new approach to the technology. They

Patients brought to the London Chest Hospital and the Heart Hospital will be recruited for the study. A stem cell sample will be taken from the patient’s bone

In July 2006, the Japanese Ministry of Health, Labour and Welfare approved Avonex for the prevention of MS relapse. Avonex is the first new MS treatment available in